About this Journal Submit a Manuscript Table of Contents
Prostate Cancer
Volume 2013 (2013), Article ID 210686, 10 pages
http://dx.doi.org/10.1155/2013/210686
Review Article

Bone-Targeted Therapies in Metastatic Castration-Resistant Prostate Cancer: Evolving Paradigms

1Division of Hematology/Oncology, Department of Medicine, George Washington University Medical Center, 2150 Pennsylvania Avenue NW, Washington, DC 20037, USA
2Department of Medicine, George Washington University Medical Center, Washington, DC 20037, USA

Received 10 June 2013; Accepted 25 July 2013

Academic Editor: William L. Dahut

Copyright © 2013 Joelle El-Amm et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. Siegel, D. Naishadham, and A. Jemal, “Cancer statistics, 2012,” CA: Cancer Journal for Clinicians, vol. 62, no. 1, pp. 10–29, 2012. View at Publisher · View at Google Scholar · View at Scopus
  2. L. Bubendorf, A. Schöpfer, U. Wagner et al., “Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients,” Human Pathology, vol. 31, no. 5, pp. 578–583, 2000. View at Scopus
  3. L. Costa, X. Badia, E. Chow, A. Lipton, and A. Wardley, “Impact of skeletal complications on patients' quality of life, mobility, and functional independence,” Supportive Care in Cancer, vol. 16, no. 8, pp. 879–889, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. P. Sabbatini, S. M. Larson, A. Kremer et al., “Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer,” Journal of Clinical Oncology, vol. 17, no. 3, pp. 948–957, 1999. View at Scopus
  5. F. Saad, D. M. Gleason, R. Murray et al., “A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma,” Journal of the National Cancer Institute, vol. 94, no. 19, pp. 1458–1468, 2002. View at Scopus
  6. F. Saad, D. M. Gleason, R. Murray et al., “Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer,” Journal of the National Cancer Institute, vol. 96, no. 11, pp. 879–882, 2004. View at Scopus
  7. E. T. Keller and J. Brown, “Prostate cancer bone metastases promote both osteolytic and osteoblastic activity,” Journal of Cellular Biochemistry, vol. 91, no. 4, pp. 718–729, 2004. View at Publisher · View at Google Scholar · View at Scopus
  8. I. F. Tannock, R. De Wit, W. R. Berry et al., “Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer,” The New England Journal of Medicine, vol. 351, no. 15, pp. 1502–1512, 2004. View at Publisher · View at Google Scholar · View at Scopus
  9. D. P. Petrylak, C. M. Tangen, M. H. A. Hussain et al., “Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer,” The New England Journal of Medicine, vol. 351, no. 15, pp. 1513–1520, 2004. View at Publisher · View at Google Scholar · View at Scopus
  10. K. Fizazi, H. I. Scher, A. Molina, et al., “Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study,” The Lancet Oncology, vol. 13, no. 10, pp. 983–992, 2012. View at Publisher · View at Google Scholar
  11. H. I. Scher, K. Fizazi, F. Saad, et al., “Increased survival with enzalutamide in prostate cancer after chemotherapy,” The New England Journal of Medicine, vol. 367, no. 13, pp. 1187–1197, 2012.
  12. C. J. Logothetis, E. Basch, A. Molina, et al., “Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial,” The Lancet Oncology, vol. 13, no. 12, pp. 1210–1217, 2012.
  13. E. Basch, C. J. Ryan, T. Kheoh, et al., “The impact of Abiraterone Acetate (AA) Therapy on patient-reported pain and functional status in chemotherapy-naive patients with progressive, metastatic castration-resistant prostate cancer (mCRPC),” Annals of Oncology, vol. 23, supplement 9, 2012, abstract 8950.
  14. K. Fizazi, H. I. Scher, F. Saad, et al., “Impact of Enzalutamide, an androgen receptor signaling inhibitor, on time to first skeletal related event (SRE) and pain in the phase 3 AFFIRM Study,” Annals of Oncology, vol. 23, supplement 9, 2012, abstract 8960.
  15. J. S. De Bono, C. J. Logothetis, A. Molina et al., “Abiraterone and increased survival in metastatic prostate cancer,” The New England Journal of Medicine, vol. 364, no. 21, pp. 1995–2005, 2011. View at Publisher · View at Google Scholar · View at Scopus
  16. K. Fizazi, M. Carducci, M. Smith et al., “Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study,” The Lancet, vol. 377, no. 9768, pp. 813–822, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. V. J. Lewington, A. J. McEwan, D. M. Ackery et al., “A prospective, randomised double-blind crossover study to examine the efficacy of strontium-89 in pain palliation in patients with advanced prostate cancer metastatic to bone,” European Journal of Cancer, vol. 27, no. 8, pp. 954–958, 1991. View at Publisher · View at Google Scholar · View at Scopus
  18. A. N. Serafini, S. J. Houston, I. Resche et al., “Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial,” Journal of Clinical Oncology, vol. 16, no. 4, pp. 1574–1581, 1998. View at Scopus
  19. O. Sartor, R. H. Reid, P. J. Hoskin et al., “Samarium-153-lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer,” Urology, vol. 63, no. 5, pp. 940–945, 2004. View at Publisher · View at Google Scholar · View at Scopus
  20. O. Sartor, R. H. Reid, D. L. Bushnell, D. P. Quick, and P. J. Ell, “Safety and efficacy of repeat administration of samarium Sm-153 lexidronam to patients with metastatic bone pain,” Cancer, vol. 109, no. 3, pp. 637–643, 2007. View at Publisher · View at Google Scholar · View at Scopus
  21. C. Parker, S. Nilsson, D. Heinrich, et al., “Updated analysis of the phase III, double-blind, randomized, multinational study of radium-223 chloride in castration-resistant prostate cancer (CRPC) patients with bone metastases (ALSYMPCA),” Journal of Clinical Oncology, vol. 30, no. 18, 2012, abstract LBA4512.
  22. G. M. Oades, J. Coxon, and K. W. Colston, “The potential role of bisphosphonates in prostate cancer,” Prostate Cancer and Prostatic Diseases, vol. 5, no. 4, pp. 264–272, 2002. View at Publisher · View at Google Scholar · View at Scopus
  23. M. J. Rogers, D. J. Watts, and R. G. G. Russell, “Overview of bisphosphonates,” Cancer, vol. 80, no. 8, pp. 1652–1660, 1997. View at Scopus
  24. E. J. Small, M. R. Smith, J. J. Seaman, S. Petrone, and M. O. Kowalski, “Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer,” Journal of Clinical Oncology, vol. 21, no. 23, pp. 4277–4284, 2003. View at Publisher · View at Google Scholar · View at Scopus
  25. D. S. Ernst, I. F. Tannock, E. W. Winquist et al., “Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain,” Journal of Clinical Oncology, vol. 21, no. 17, pp. 3335–3342, 2003. View at Publisher · View at Google Scholar · View at Scopus
  26. D. P. Dearnaley, M. R. Sydes, M. D. Mason et al., “A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial),” Journal of the National Cancer Institute, vol. 95, no. 17, pp. 1300–1311, 2003. View at Scopus
  27. D. P. Dearnaley, M. D. Mason, M. K. Parmar, K. Sanders, and M. R. Sydes, “Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials,” The The Lancet Oncologyogy, vol. 10, no. 9, pp. 872–876, 2009. View at Publisher · View at Google Scholar · View at Scopus
  28. J. B. Aragon-Ching, “Further analysis of the survival benefit of clodronate,” Cancer Biology and Therapy, vol. 8, no. 23, pp. 2221–2222, 2009. View at Scopus
  29. F. Saad, J. E. Brown, C. Van Poznak et al., “Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases,” Annals of Oncology, vol. 23, no. 5, pp. 1341–1347, 2012. View at Publisher · View at Google Scholar · View at Scopus
  30. J. B. Aragon-Ching, Y.-M. Ning, C. C. Chen et al., “Higher incidence of Osteonecrosis of the Jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agents,” Cancer Investigation, vol. 27, no. 2, pp. 221–226, 2009. View at Publisher · View at Google Scholar · View at Scopus
  31. S. Ruggiero, J. Gralow, R. E. Marx, et al., “Practical guidelines for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in patients with cancer,” Journal of Oncology Practice, vol. 2, no. 1, pp. 7–14, 2006.
  32. P. Conte and V. Guarneri, “Safety of intravenous and oral bisphosphonates and compliance with dosing regimens,” Oncologist, vol. 9, no. 4, pp. 28–37, 2004. View at Publisher · View at Google Scholar · View at Scopus
  33. G. B. Kasting and M. D. Francis, “Retention of etidronate in human, dog, and rat,” Journal of Bone and Mineral Research, vol. 7, no. 5, pp. 513–522, 1992. View at Scopus
  34. K. Matsuzaki, N. Udagawa, N. Takahashi et al., “Osteoclast differentiation factor (ODF) induces osteoclast-like cell formation in human peripheral blood mononuclear cell cultures,” Biochemical and Biophysical Research Communications, vol. 246, no. 1, pp. 199–204, 1998. View at Publisher · View at Google Scholar · View at Scopus
  35. H. Yasuda, N. Shima, N. Nakagawa et al., “Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL,” Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 7, pp. 3597–3602, 1998. View at Publisher · View at Google Scholar · View at Scopus
  36. T. L. Burgess, Y.-X. Qian, S. Kaufman et al., “The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts,” Journal of Cell Biology, vol. 145, no. 3, pp. 527–538, 1999. View at Publisher · View at Google Scholar · View at Scopus
  37. E. A. O'Brien, J. H. H. Williams, and M. J. Marshall, “Osteoprotegerin ligand regulates osteoclast adherence to the bone surface in mouse calvaria,” Biochemical and Biophysical Research Communications, vol. 274, no. 2, pp. 281–290, 2000. View at Publisher · View at Google Scholar · View at Scopus
  38. D. L. Lacey, H. L. Tan, J. Lu et al., “Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo,” American Journal of Pathology, vol. 157, no. 2, pp. 435–448, 2000. View at Scopus
  39. T. Wada, T. Nakashima, N. Hiroshi, and J. M. Penninger, “RANKL-RANK signaling in osteoclastogenesis and bone disease,” Trends in Molecular Medicine, vol. 12, no. 1, pp. 17–25, 2006. View at Publisher · View at Google Scholar · View at Scopus
  40. J.-J. Body, T. Facon, R. E. Coleman et al., “A study of the biological receptor activator of nuclear factor-κ ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer,” Clinical Cancer Research, vol. 12, no. 4, pp. 1221–1228, 2006. View at Publisher · View at Google Scholar · View at Scopus
  41. K. Fizazi, A. Lipton, X. Mariette et al., “Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates,” Journal of Clinical Oncology, vol. 27, no. 10, pp. 1564–1571, 2009. View at Publisher · View at Google Scholar · View at Scopus
  42. S. Rajpar, C. Massard, A. Laplanche et al., “Urinary N-telopeptide (uNTx) is an independent prognostic factor for overall survival in patients with bone metastases from castration-resistant prostate cancer,” Annals of Oncology, vol. 21, no. 9, pp. 1864–1869, 2010. View at Publisher · View at Google Scholar · View at Scopus
  43. M. R. Smith, B. Egerdie, N. H. Toriz et al., “Denosumab in men receiving androgen-deprivation therapy for prostate cancer,” The New England Journal of Medicine, vol. 361, no. 8, pp. 745–755, 2009. View at Publisher · View at Google Scholar · View at Scopus
  44. M. R. Smith, F. Saad, R. Coleman et al., “Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial,” The Lancet, vol. 379, no. 9810, pp. 39–46, 2012. View at Publisher · View at Google Scholar · View at Scopus
  45. J. Goyal and E. S. Antonarakis, “Bone-targeting radiopharmaceuticals for the treatment of prostate cancer with bone metastases,” Cancer Letters, 2012. View at Publisher · View at Google Scholar · View at Scopus
  46. A. Adam, A. K. Dixon, D. J. Allison, and R. G. Grainger, Grainger and Allison's Diagnostic Radiology: A Textbook of Medical Imaging, Churchill Livingstone, Edinburgh, UK, 5th edition, 2008.
  47. K. Buchali, H.-J. Correns, M. Schuerer, D. Schnorr, H. Lips, and K. Sydow, “Results of a double blind study of 89-strontium therapy of skeletal metastases of prostatic carcinoma,” European Journal of Nuclear Medicine, vol. 14, no. 7-8, pp. 349–351, 1988. View at Scopus
  48. A. T. Porter, A. J. B. McEwan, J. E. Powe et al., “Results of a randomized Phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer,” International Journal of Radiation Oncology Biology Physics, vol. 25, no. 5, pp. 805–813, 1993. View at Scopus
  49. P. M. Quilty, “A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer,” Radiotherapy and Oncology, vol. 31, no. 1, pp. 33–40, 1994. View at Publisher · View at Google Scholar · View at Scopus
  50. G. O. N. Oosterhof, J. T. Roberts, T. M. De Reijke et al., “Strontium(89) chloride versus palliative local field radiotherapy in patients with hormonal escaped prostate cancer: a phase III study of the European Organisation for Research and Treatment of Cancer, Genitourinary Group,” European Urology, vol. 44, no. 5, pp. 519–526, 2003. View at Publisher · View at Google Scholar · View at Scopus
  51. M. Roque, M. J. Martinez, P. Alonso, E. Catala, J. L. Garcia, and M. Ferrandiz, “Radioisotopes for metastatic bone pain,” Cochrane Database of Systematic Reviews, no. 4, Article ID CD003347, 2003.
  52. A. H. Laing, D. M. Ackery, R. J. Bayly et al., “Strontium-89 chloride for pain palliation in prostatic skeletal malignancy,” British Journal of Radiology, vol. 64, no. 765, pp. 817–822, 1991. View at Scopus
  53. I. G. Finlay, M. D. Mason, and M. Shelley, “Radioisotopes for the palliation of metastatic bone cancer: a systematic review,” The Lancet Oncologyogy, vol. 6, no. 6, pp. 392–400, 2005. View at Publisher · View at Google Scholar · View at Scopus
  54. E. B. Silberstein and C. Williams, “Strontium-89 therapy for the pain of osseous metastases,” Journal of Nuclear Medicine, vol. 26, no. 4, pp. 345–348, 1985. View at Scopus
  55. F. Pons, R. Herranz, A. Garcia et al., “Strontium-89 for palliation of pain from bone metastases in patients with prostate and breast cancer,” European Journal of Nuclear Medicine, vol. 24, no. 10, pp. 1210–1214, 1997. View at Publisher · View at Google Scholar · View at Scopus
  56. J. H. Turner, P. G. Claringbold, E. L. Hetherington, P. Sorby, and A. A. Martindale, “A phase I study of samarium-153 ethylenediaminetetramethylene phosphonate therapy for disseminated skeletal metastases,” Journal of Clinical Oncology, vol. 7, no. 12, pp. 1926–1931, 1989. View at Scopus
  57. I. Resche, J.-F. Chatal, A. Pecking et al., “A dose-controlled study of 153Sm-ethylenediaminetetramethylenephosphonate (EDTMP) in the treatment of patients with painful bone metastases,” European Journal of Cancer, vol. 33, no. 10, pp. 1583–1591, 1997. View at Publisher · View at Google Scholar · View at Scopus
  58. P. J. Cheetham and D. P. Petrylak, “Alpha particles as radiopharmaceuticals in the treatment of bone metastases: mechanism of action of radium-223 chloride (Alpharadin) and radiation,” Oncology, vol. 26, no. 4, pp. 330–337, 341, 2012. View at Scopus
  59. S. Nilsson, L. Franzén, C. Parker et al., “Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study,” The Lancet Oncologyogy, vol. 8, no. 7, pp. 587–594, 2007. View at Publisher · View at Google Scholar · View at Scopus
  60. S. Nilsson, R. H. Larsen, S. D. Fosså et al., “First clinical experience with α-emitting radium-223 in the treatment of skeletal metastases,” Clinical Cancer Research, vol. 11, no. 12, pp. 4451–4459, 2005. View at Publisher · View at Google Scholar · View at Scopus
  61. M. J. Morris, N. Pandit-Taskar, J. Carrasquillo et al., “Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancer,” Journal of Clinical Oncology, vol. 27, no. 15, pp. 2436–2442, 2009. View at Publisher · View at Google Scholar · View at Scopus
  62. S.-M. Tu, P. Mathew, F. C. Wong, D. Jones, M. M. Johnson, and C. J. Logothetis, “Phase I study of concurrent weekly docetaxel and repeated samarium-153 lexidronam in patients with castration-resistant metastatic prostate cancer,” Journal of Clinical Oncology, vol. 27, no. 20, pp. 3319–3324, 2009. View at Publisher · View at Google Scholar · View at Scopus
  63. M. J. Morris, H. J. Hammers, C. Sweeney, et al., “Safety of radium-223 dichloride (Ra-223) with docetaxel (D) in patients with bone metastases from castration-resistant prostate cancer (CRPC): a phase I Prostate Cancer Clinical Trials Consortium Study,” Journal of Clinical Oncology, vol. 31, 2013, abstract 5021.
  64. K. Fizazi, P. Beuzeboc, J. Lumbroso et al., “Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer,” Journal of Clinical Oncology, vol. 27, no. 15, pp. 2429–2435, 2009. View at Publisher · View at Google Scholar · View at Scopus
  65. S.-M. Tu, R. E. Millikan, B. Mengistu et al., “Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial,” The Lancet, vol. 357, no. 9253, pp. 336–341, 2001. View at Publisher · View at Google Scholar · View at Scopus
  66. N. D. James, S. Pirrie, D. Barton, et al., “Clinical outcomes in patients with castrate-refractory prostate cancer (CRPC) metastatic to bone randomized in the factorial TRAPEZE trial to docetaxel (D) with strontium-89 (Sr89), zoledronic acid (ZA), neither, or both (ISRCTN 12808747),” Journal of Clinical Oncology, vol. 31, 2013, abstract LBA5000.
  67. D. C. Smith, M. R. Smith, C. Sweeney, et al., “Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial,” Journal of Clinical Oncology, vol. 31, no. 4, pp. 412–419, 2013.
  68. R. J. Lee, P. J. Saylor, M. D. Michaelson, et al., “A dose-ranging study of cabozantinib in men with castration-resistant prostate cancer and bone metastases,” Clinical Cancer Research, vol. 19, no. 11, pp. 3088–3094, 2013. View at Publisher · View at Google Scholar
  69. F. Saad and A. Lipton, “SRC kinase inhibition: targeting bone metastases and tumor growth in prostate and breast cancer,” Cancer Treatment Reviews, vol. 36, no. 2, pp. 177–184, 2010. View at Publisher · View at Google Scholar · View at Scopus
  70. J. C. Araujo, P. Mathew, A. J. Armstrong et al., “Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1-2 study,” Cancer, vol. 118, no. 1, pp. 63–71, 2012. View at Publisher · View at Google Scholar · View at Scopus
  71. E. Y. Yu, G. Wilding, E. Posadas et al., “Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer,” Clinical Cancer Research, vol. 15, no. 23, pp. 7421–7428, 2009. View at Publisher · View at Google Scholar · View at Scopus
  72. J. C. Araujo, G. C. Trudel, F. Saad, et al., “Overall survival (OS) and safety of dasatinib/docetaxel versus docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC): results from the randomized phase III READY trial,” Journal of Clinical Oncology, vol. 6, 2013, abstract LBA8.
  73. E. Y. Yu, F. Duan, M. Muzi, et al., “Correlation of 18F-fluoride PET response to dasatinib in castration-resistant prostate cancer bone metastases with progression-free survival: preliminary results from ACRIN 6687,” Journal of Clinical Oncology, vol. 31, 2013, abstract 5003.
  74. J. S. De Bono, S. Oudard, M. Ozguroglu et al., “Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial,” The Lancet, vol. 376, no. 9747, pp. 1147–1154, 2010. View at Publisher · View at Google Scholar · View at Scopus
  75. C. J. Ryan, A. Molina, and T. Griffin, “Abiraterone in metastatic prostate cancer,” The New England Journal of Medicine, vol. 368, no. 15, pp. 1458–1459, 2013.